Full Year 2024 Hikma Pharmaceuticals PLC Earnings Call Transcript
Key Points
- Hikma Pharmaceuticals PLC (HKMPF) achieved a group core revenue growth of 10% in 2024, surpassing their upgraded guidance of 6% to 8%.
- The company delivered a core operating profit of $719 million, aligning with their guidance despite challenges in the Generic business.
- Hikma Pharmaceuticals PLC (HKMPF) launched 132 products across the business in 2024, including the first approved ANDA for GLP-1 referencing Victoza in the US.
- The company is investing in expanding its manufacturing capacity and capabilities, with new plants in Morocco and Algeria expected to be operational by 2026.
- Hikma Pharmaceuticals PLC (HKMPF) is focusing on strategic investments, including the acquisition of Xellia's US assets and R&D center, to enhance their pipeline and market presence.
- The Generic business faced profit headwinds due to increased royalties on their authorized generic of sodium oxybate.
- Injectable core operating margin contracted to 35.3% from 36.9% in 2023, partly due to the slightly dilutive impact of the Xellia acquisition.
- The company expects Generic revenue to be broadly flat in 2025, with price erosion impacting the base business.
- Hikma Pharmaceuticals PLC (HKMPF) plans to increase R&D spending by 20% in 2025, which may impact short-term profitability.
- The company's total debt increased to $1.3 billion due to the Xellia acquisition, affecting their net debt to core EBITDA ratio.
Thank you for joining our 2024 full-year results presentation. I'm Riad Mishlawi, CEO of Hikma, and I'm joined here with Khalid Nabilsi, our CFO. I will kick off by providing a quick summary of our results and an update on our strategic progress. I will then hand over to Khalid, to take us through the financials in more details.
I've been in the CEO role now for about just over a year, and I'm pleased with the progress we've made to date. We delivered an excellent financial performance ahead of our initial expectations, and I'm very confident that we have the right strategy in place to deliver growth for many years to come.
We achieved group core revenue growth of 10% in 2024 ahead of our upgraded guidance of 6% to 8% for the year. Demonstrating the strength of our three business segments, each unique, but together, providing differentiation, diversification, and exciting potential.
We also delivered core operating profit of $719 million, in line with our guidance. This is a great result,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
